

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Type or print name of person signing certification

Signature

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: Jeffrey Alan Dodge

Group Art Unit:

International Application Date: January 18, 2005

Conf No.:

For: SELECTIVE ESTROGEN RECEPTOR MODULATORS

Docket No.: X16065

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Gilbert T. Voy/

Gilbert T. Voy
Attorney for Applicants
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

June 20, 2006

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16065	Serial No
	First Applicant Jeffrey Alan Dodge	
	Application Date US Nat'l Entry (if applicable)	Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	EP 0 761 669	03-12-1997	Eli Lilly and Company	Page 43; example 11b	
	BB	WO 03/053977	07-03-2003	Ortho-McNeil Pharmaceutical, Inc.	Claim 1	
	BC	EP 0 761 659	03-12-1997	Eli Lilly and Company	Page 1, Line 3 – 7; examples 2, 5, 6	
	BD	WO 95/10513	04-20-1995	Pfizer Inc.; et al.	Table 2, p. 76, 2 nd structural formula; p. 77, 2 nd structural formula abstract; example 19	
	BE	EP 0 729 951	09-04-1996	Eli Lilly and Company	The whole document	
	BF	EP 0 731 100	09-11-1996	Eli Lilly and Company	The whole document	
	BG	EP 0 791 591	08-27-1997	Eli Lilly and Company	Examples p. 5, line 52 – line 54; claim 1	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16065	Serial No
	First Applicant Jeffrey Alan Dodge	
	Application Date US Nat'l Entry (if applicable)	Group Art Unit

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Grese T. A., et al., "Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators", <i>Journal of Organic Chemistry</i> , Washington, USA, vol. 41, no. 8, pages 1272-1283, 1998.	
	CB	Grese T. A., et al., "Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-Arylbenzothiophene core of raloxifene" <i>Journal of Medicinal Chemistry</i> , American Chemical Society, vol. 40, no. 2, pages 146-167, 1997.	
	CC		
	CD		
	CE		
	CF		
	CG		
	CH		
	CI		
	CJ		
	CK		
	CL		
	CM		

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.